CARY, NC – The U.S. Patent Office has awarded three patents to BioLink Life Sciences Inc. for four novel epilepsy drugs.

“Most epileptic patients take valproate drugs like Depakote to treat their disease,” BioLink’s president Deanna Nelson noted.

“Current valproate drugs cause nausea, lethargy, weight gain, and other more serious side effects. In contrast, each of BioLink’s four new valproates is formulated to cause fewer side effects while providing the valproate drug that the patient needs.”

Valproates are used for the treatment of epilepsy, bipolar disorders, and migraines.

New uses of valproates as treatments for Alzheimer’s disease and cancer are being evaluated in clinical trials. BioLink says it will work with strategic partners to gain FDA approval for each of its new valproate drugs.

BioLink “repairs” drugs to reduce side effects and improve their safety, a strategy that significantly reduces the time and cost of development for FDA approval.

The company works with pharmaceutical partners to commercialize, market, and distribute its drug candidates.

On the Web: www.biolink.org

© 2008, TechJournal South. All rights reserved.